Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Everything you need to know about the new Wegovy pill – and whether you should take it or not

LET’S UNPACK THAT: With massive demand for the GLP-1 tablets as they are approved for use in the UK, Helen Coffey asks experts how they differ from the jab and whether they are the next big step in the weight-loss revolution

The Independent UK

Novo Nordisk reveals cyberattack: Ozempic and Wegovy maker says clinical trials data breached

Novo Nordisk reveals cyberattack: Ozempic and Wegovy maker says clinical trials data breached

The company says the data is pseudonymous and apparently can't be linked to actual people.

UK approves Novo weight-loss pill to edge open European market

UK approves Novo weight-loss pill to edge open European market

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity in the UK now have an alternative to injections. Drugmakers are racing to expand use of these transformative medicines. The market is expected…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA issues new kidney warning for weight loss pill

Alli was the first over-the-counter weight loss pill approved by the U.S. Food and Drug Administration

The Independent UK

Medicare Is About to Cover Weight-Loss Drugs for the First Time — Here's What the GLP-1 Bridge Program Means for Millions of Americans with Obesity

Medicare's GLP-1 Bridge launches July 1, 2026, offering eligible Part D enrollees Wegovy and Zepbound for $50/month — the first-ever Medicare coverage for obesity-specific GLP-1 drugs.

From Crisis to Possible Cure Path: San Antonio Battles Highest Diabetes Rates as Wegovy and Medicare (United States) Expansion Offer New Hope

Diabetes care is entering a new era in San Antonio as the Wegovy pill and expanded Medicare coverage offer new hope for preventing and managing diabetes in one of America's hardest-hit cities.

5 Best Growth Stocks for the Next 10 Years

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

inkl

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk uses AI to fast-track drug launches, expand India role

Novo Nordisk uses AI to fast-track drug launches, expand India role

Novo Nordisk is leveraging Artificial Intelligence to significantly speed up new drug launches. The company expects to cut down the time to market by as much as two-thirds. Its center in Bengaluru, India, is becoming crucial for global drug preparations.

The Economic Times

The Silver Lining of Last Week's Hims & Hers Earnings Miss

The Silver Lining of Last Week's Hims & Hers Earnings Miss

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

Singapore Court of Appeal Notes No Finding of Fraud Against KBP or Dr. Huang; Dispute with Novo Nordisk Undergoing Arbitration Proceedings

SINGAPORE, May 21, 2026 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company" or "KBP") today issued a statement addressing the decision by the Singapore Court of Appeal to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr. Huang"), pending final resolution of the arbitration proceedings…

CEOs are getting ruthless about worker performance

CEOs are getting ruthless about worker performance

Corporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volume growth, positive mix, consistent growth margin expansion." This shift towards "performance cultures" involves tougher accountability, potential layoffs, and a focus on tangible outcomes, signaling a departure from the more empathetic approach of the…

The Economic Times

This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Hims & Hers delivered a sharp earnings miss as GLP-1 and international expansion costs surged. Investors now face a classic tradeoff between near-term margins and long-term growth.

Dr. Reddy's Laboratories Q4 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter. Narasimham said the company’s und

Get all your
news in one place.

100's of premium titles.
One news app.

Omeros Q1 Earnings Call Highlights

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive

Novo Nordisk A/S Q1 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

The Economic Times

Mark Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy

Last October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development ‌of ⁠the therapy.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Novo Nordisk boosted as sales of Wegovy weight loss pills soar

The Independent UK

Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly

Evening Standard

Wegovy maker Novo Nordisk boosted by successful weight loss pill launch

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

International Business Times UK

Hershey's CEO Claims Ozempic Breath is Driving Massive Surge in Mint and Gum Sales Across the United States

Hershey's CEO attributes an 8% sales increase in Ice Breakers mints and gum to the side effects of GLP-1 weight-loss drugs, highlighting an unexpected revenue driver.

The Independent UK

Trump team delays pilot program for Medicare to cover cost of ‘fat shot’

Without insurance or discounts, GLP-1 injectables can cost more than $1,000 per month

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.

1 2 3 4 5

People

198,013 stories

Mark Zuckerberg

Philipp Navratil

Fernando Fernandez

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Court of Appeal

the Court of Appeal

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

389,441 stories

142,331 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play